Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 462 | 2023 | 20774 | 12.920 |
Why?
|
Receptor, erbB-2 | 146 | 2023 | 2410 | 10.000 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 189 | 2023 | 11472 | 7.170 |
Why?
|
Paclitaxel | 69 | 2023 | 1707 | 5.050 |
Why?
|
Aromatase Inhibitors | 39 | 2021 | 491 | 4.500 |
Why?
|
Receptors, Estrogen | 77 | 2022 | 2186 | 3.960 |
Why?
|
Chemotherapy, Adjuvant | 120 | 2022 | 3471 | 3.930 |
Why?
|
Antineoplastic Agents, Hormonal | 49 | 2022 | 1509 | 3.280 |
Why?
|
Tamoxifen | 43 | 2022 | 980 | 3.010 |
Why?
|
Quinazolines | 27 | 2021 | 1355 | 2.570 |
Why?
|
Antineoplastic Agents | 87 | 2022 | 13655 | 2.490 |
Why?
|
Neoadjuvant Therapy | 45 | 2022 | 2721 | 2.210 |
Why?
|
Receptors, Progesterone | 41 | 2022 | 1097 | 2.140 |
Why?
|
Breast Neoplasms, Male | 9 | 2023 | 210 | 1.870 |
Why?
|
Neoplasm Recurrence, Local | 54 | 2023 | 9185 | 1.690 |
Why?
|
Brain Neoplasms | 30 | 2023 | 8829 | 1.690 |
Why?
|
Carcinoma, Ductal, Breast | 15 | 2022 | 1101 | 1.670 |
Why?
|
Medical Oncology | 18 | 2021 | 2235 | 1.620 |
Why?
|
Female | 497 | 2023 | 379592 | 1.560 |
Why?
|
Nitriles | 20 | 2021 | 952 | 1.540 |
Why?
|
Neoplasm Staging | 97 | 2022 | 11001 | 1.530 |
Why?
|
Disease-Free Survival | 69 | 2022 | 6891 | 1.510 |
Why?
|
Triazoles | 19 | 2017 | 907 | 1.510 |
Why?
|
Vinblastine | 18 | 2013 | 490 | 1.450 |
Why?
|
Pyridines | 14 | 2022 | 2818 | 1.300 |
Why?
|
Neoplasm Metastasis | 63 | 2021 | 4839 | 1.290 |
Why?
|
Cyclophosphamide | 42 | 2020 | 2236 | 1.220 |
Why?
|
Humans | 557 | 2023 | 742088 | 1.210 |
Why?
|
Mastectomy, Segmental | 22 | 2021 | 955 | 1.210 |
Why?
|
Fluorouracil | 30 | 2019 | 1615 | 1.200 |
Why?
|
Carboplatin | 11 | 2022 | 799 | 1.180 |
Why?
|
Middle Aged | 286 | 2023 | 213127 | 1.180 |
Why?
|
Doxorubicin | 42 | 2020 | 2215 | 1.180 |
Why?
|
Antineoplastic Agents, Phytogenic | 13 | 2016 | 623 | 1.150 |
Why?
|
Postmenopause | 24 | 2022 | 2461 | 1.130 |
Why?
|
Deoxycytidine | 19 | 2014 | 824 | 1.120 |
Why?
|
Clinical Trials as Topic | 31 | 2020 | 7901 | 1.110 |
Why?
|
Aged | 252 | 2022 | 162944 | 1.100 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 12 | 2015 | 947 | 1.080 |
Why?
|
Antibodies, Monoclonal | 31 | 2018 | 9274 | 1.060 |
Why?
|
Oxazoles | 4 | 2021 | 189 | 1.040 |
Why?
|
Epothilones | 5 | 2021 | 44 | 1.000 |
Why?
|
Adult | 249 | 2022 | 213712 | 0.980 |
Why?
|
Protein Kinase Inhibitors | 19 | 2022 | 5522 | 0.970 |
Why?
|
Treatment Outcome | 124 | 2023 | 62966 | 0.960 |
Why?
|
Maytansine | 6 | 2021 | 80 | 0.940 |
Why?
|
Consensus Development Conferences as Topic | 4 | 2019 | 170 | 0.940 |
Why?
|
Survival Analysis | 41 | 2022 | 10248 | 0.910 |
Why?
|
Mammography | 12 | 2021 | 2474 | 0.910 |
Why?
|
Taxoids | 13 | 2022 | 665 | 0.910 |
Why?
|
Carcinoma, Lobular | 9 | 2022 | 484 | 0.910 |
Why?
|
Mastectomy | 33 | 2022 | 1789 | 0.880 |
Why?
|
Neoplasms, Hormone-Dependent | 9 | 2014 | 414 | 0.880 |
Why?
|
Survivors | 20 | 2021 | 2286 | 0.870 |
Why?
|
Albumins | 8 | 2021 | 568 | 0.860 |
Why?
|
Cisplatin | 13 | 2021 | 1637 | 0.830 |
Why?
|
Quality of Life | 40 | 2022 | 12730 | 0.810 |
Why?
|
Genes, BRCA1 | 18 | 2018 | 780 | 0.810 |
Why?
|
Piperazines | 12 | 2022 | 2488 | 0.740 |
Why?
|
Drug Resistance, Neoplasm | 26 | 2022 | 5163 | 0.730 |
Why?
|
Anilides | 3 | 2019 | 404 | 0.720 |
Why?
|
Aged, 80 and over | 103 | 2021 | 57683 | 0.710 |
Why?
|
Antimetabolites, Antineoplastic | 8 | 2019 | 640 | 0.710 |
Why?
|
Prognosis | 65 | 2022 | 29010 | 0.700 |
Why?
|
Antibiotics, Antineoplastic | 8 | 2021 | 692 | 0.690 |
Why?
|
Anthracyclines | 12 | 2021 | 288 | 0.690 |
Why?
|
Disclosure | 4 | 2009 | 736 | 0.680 |
Why?
|
Drug Administration Schedule | 36 | 2020 | 4929 | 0.660 |
Why?
|
Kaplan-Meier Estimate | 32 | 2021 | 6534 | 0.650 |
Why?
|
Trinitrotoluene | 1 | 2018 | 6 | 0.650 |
Why?
|
Interdisciplinary Communication | 5 | 2021 | 950 | 0.650 |
Why?
|
Aminopyridines | 8 | 2022 | 541 | 0.640 |
Why?
|
Survival Rate | 43 | 2021 | 12773 | 0.640 |
Why?
|
Granulocyte Colony-Stimulating Factor | 8 | 2016 | 647 | 0.640 |
Why?
|
Exercise Therapy | 4 | 2019 | 904 | 0.640 |
Why?
|
Lymphatic Metastasis | 27 | 2021 | 2906 | 0.620 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 8 | 2021 | 890 | 0.610 |
Why?
|
Platinum Compounds | 3 | 2015 | 96 | 0.590 |
Why?
|
Fertility | 3 | 2008 | 770 | 0.570 |
Why?
|
Phthalazines | 6 | 2022 | 361 | 0.570 |
Why?
|
Androstadienes | 7 | 2020 | 346 | 0.570 |
Why?
|
Protein-Tyrosine Kinases | 3 | 2020 | 2455 | 0.570 |
Why?
|
Exercise | 9 | 2021 | 5611 | 0.560 |
Why?
|
Quinolines | 7 | 2022 | 719 | 0.560 |
Why?
|
SEER Program | 20 | 2022 | 1507 | 0.560 |
Why?
|
Breast | 14 | 2023 | 1958 | 0.550 |
Why?
|
Combined Modality Therapy | 34 | 2021 | 8621 | 0.550 |
Why?
|
Genes, erbB-2 | 7 | 2011 | 162 | 0.540 |
Why?
|
Enzyme Inhibitors | 9 | 2010 | 3800 | 0.530 |
Why?
|
Neutropenia | 8 | 2022 | 891 | 0.520 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 4 | 2021 | 1038 | 0.520 |
Why?
|
Practice Guidelines as Topic | 14 | 2019 | 7276 | 0.510 |
Why?
|
Menopause | 7 | 2009 | 1621 | 0.480 |
Why?
|
Peripheral Nervous System Diseases | 6 | 2019 | 700 | 0.480 |
Why?
|
Physical Fitness | 3 | 2016 | 732 | 0.470 |
Why?
|
Mutation | 37 | 2022 | 29717 | 0.470 |
Why?
|
Neoplasms, Second Primary | 5 | 2016 | 1052 | 0.470 |
Why?
|
Premenopause | 11 | 2018 | 1033 | 0.460 |
Why?
|
Randomized Controlled Trials as Topic | 24 | 2018 | 9941 | 0.450 |
Why?
|
Body Mass Index | 7 | 2021 | 12695 | 0.450 |
Why?
|
Clinical Trials, Phase III as Topic | 7 | 2013 | 839 | 0.450 |
Why?
|
Gene Expression Regulation, Neoplastic | 13 | 2021 | 8425 | 0.440 |
Why?
|
Filgrastim | 8 | 2020 | 132 | 0.440 |
Why?
|
Follow-Up Studies | 50 | 2021 | 39004 | 0.440 |
Why?
|
Ovarian Neoplasms | 14 | 2020 | 4823 | 0.440 |
Why?
|
Adaptation, Psychological | 7 | 2014 | 2575 | 0.440 |
Why?
|
Age Factors | 34 | 2019 | 18355 | 0.430 |
Why?
|
Genetic Testing | 13 | 2021 | 3439 | 0.420 |
Why?
|
Dose-Response Relationship, Drug | 27 | 2019 | 10943 | 0.420 |
Why?
|
Estrogen Receptor Modulators | 5 | 2010 | 61 | 0.420 |
Why?
|
Colony-Stimulating Factors | 1 | 2012 | 216 | 0.420 |
Why?
|
Lymph Node Excision | 9 | 2017 | 1248 | 0.420 |
Why?
|
Central Nervous System Neoplasms | 5 | 2013 | 895 | 0.420 |
Why?
|
Immunity | 1 | 2018 | 1011 | 0.410 |
Why?
|
Estrogen Receptor alpha | 4 | 2020 | 577 | 0.400 |
Why?
|
Attitude of Health Personnel | 7 | 2020 | 3839 | 0.400 |
Why?
|
Body Weight | 2 | 2021 | 4664 | 0.400 |
Why?
|
Radiotherapy | 12 | 2017 | 1525 | 0.390 |
Why?
|
Disease Progression | 25 | 2021 | 13256 | 0.380 |
Why?
|
Genes, BRCA2 | 8 | 2018 | 617 | 0.380 |
Why?
|
Population Surveillance | 4 | 2017 | 2616 | 0.380 |
Why?
|
Pneumonia, Pneumocystis | 2 | 2015 | 247 | 0.370 |
Why?
|
Research Subjects | 4 | 2007 | 238 | 0.370 |
Why?
|
Palliative Care | 5 | 2020 | 3478 | 0.370 |
Why?
|
Estrogen Antagonists | 4 | 2022 | 151 | 0.370 |
Why?
|
Decision Making | 8 | 2017 | 3869 | 0.370 |
Why?
|
Radiotherapy, Adjuvant | 15 | 2019 | 1769 | 0.370 |
Why?
|
Amenorrhea | 3 | 2021 | 485 | 0.360 |
Why?
|
Informed Consent | 4 | 2011 | 991 | 0.360 |
Why?
|
Proportional Hazards Models | 23 | 2023 | 12344 | 0.360 |
Why?
|
United States | 58 | 2021 | 69693 | 0.360 |
Why?
|
Furans | 2 | 2021 | 194 | 0.360 |
Why?
|
Ketones | 2 | 2021 | 189 | 0.360 |
Why?
|
Neoplasms | 27 | 2021 | 21596 | 0.350 |
Why?
|
Life Style | 3 | 2013 | 3824 | 0.340 |
Why?
|
Societies, Medical | 10 | 2020 | 3740 | 0.340 |
Why?
|
Preoperative Care | 6 | 2019 | 2245 | 0.340 |
Why?
|
Cyclin-Dependent Kinase 4 | 5 | 2022 | 535 | 0.340 |
Why?
|
Purines | 4 | 2022 | 593 | 0.340 |
Why?
|
Physical Endurance | 2 | 2009 | 370 | 0.330 |
Why?
|
Thiazoles | 6 | 2022 | 1484 | 0.330 |
Why?
|
Guidelines as Topic | 2 | 2018 | 1402 | 0.330 |
Why?
|
Endpoint Determination | 3 | 2021 | 600 | 0.330 |
Why?
|
Bone Marrow Transplantation | 4 | 2005 | 2763 | 0.330 |
Why?
|
Neoplastic Cells, Circulating | 4 | 2021 | 933 | 0.320 |
Why?
|
Neoplasm Invasiveness | 11 | 2019 | 3612 | 0.310 |
Why?
|
Maximum Tolerated Dose | 9 | 2021 | 891 | 0.300 |
Why?
|
Healthcare Disparities | 7 | 2015 | 3151 | 0.300 |
Why?
|
Breast Diseases | 2 | 2007 | 443 | 0.300 |
Why?
|
Molecular Targeted Therapy | 9 | 2018 | 2723 | 0.300 |
Why?
|
Neoplasm Proteins | 6 | 2010 | 3691 | 0.300 |
Why?
|
Biopsy | 9 | 2022 | 6756 | 0.300 |
Why?
|
Cohort Studies | 36 | 2023 | 40450 | 0.300 |
Why?
|
Sentinel Lymph Node Biopsy | 8 | 2017 | 701 | 0.290 |
Why?
|
Time Factors | 33 | 2022 | 40054 | 0.290 |
Why?
|
Medication Adherence | 4 | 2014 | 2055 | 0.290 |
Why?
|
Estrogens | 2 | 2021 | 1562 | 0.290 |
Why?
|
Ovary | 2 | 2016 | 981 | 0.290 |
Why?
|
Morpholines | 3 | 2020 | 561 | 0.290 |
Why?
|
Health Knowledge, Attitudes, Practice | 7 | 2020 | 3915 | 0.290 |
Why?
|
Prospective Studies | 39 | 2023 | 53187 | 0.280 |
Why?
|
Leukemia, Myeloid, Acute | 6 | 2022 | 3497 | 0.280 |
Why?
|
Neoplasm, Residual | 5 | 2022 | 974 | 0.280 |
Why?
|
Young Adult | 35 | 2021 | 56350 | 0.280 |
Why?
|
Polyethylene Glycols | 6 | 2020 | 1181 | 0.280 |
Why?
|
Genomics | 7 | 2021 | 5692 | 0.280 |
Why?
|
Patient Participation | 7 | 2015 | 1445 | 0.280 |
Why?
|
Cyclin-Dependent Kinase 6 | 3 | 2018 | 322 | 0.270 |
Why?
|
Risk Factors | 43 | 2022 | 72145 | 0.270 |
Why?
|
Carcinoma in Situ | 2 | 2010 | 802 | 0.270 |
Why?
|
Repressor Proteins | 2 | 2017 | 3020 | 0.270 |
Why?
|
Biomedical Research | 7 | 2020 | 3306 | 0.270 |
Why?
|
Health Care Reform | 2 | 2012 | 1261 | 0.270 |
Why?
|
BRCA1 Protein | 6 | 2022 | 1145 | 0.270 |
Why?
|
Carcinoma | 4 | 2015 | 2374 | 0.260 |
Why?
|
Lymph Nodes | 8 | 2019 | 3465 | 0.260 |
Why?
|
Referral and Consultation | 4 | 2020 | 3527 | 0.260 |
Why?
|
Patient Care Team | 8 | 2013 | 2527 | 0.260 |
Why?
|
Carbazoles | 1 | 2006 | 226 | 0.250 |
Why?
|
Tumor Microenvironment | 6 | 2021 | 3564 | 0.250 |
Why?
|
Double-Blind Method | 11 | 2020 | 12017 | 0.250 |
Why?
|
Ki-67 Antigen | 5 | 2021 | 644 | 0.250 |
Why?
|
BRCA2 Protein | 5 | 2020 | 790 | 0.250 |
Why?
|
Genetic Predisposition to Disease | 11 | 2021 | 17400 | 0.240 |
Why?
|
Infusions, Intravenous | 9 | 2020 | 2271 | 0.240 |
Why?
|
Logistic Models | 17 | 2021 | 13403 | 0.230 |
Why?
|
Muscle Strength | 1 | 2008 | 586 | 0.230 |
Why?
|
Remission Induction | 6 | 2016 | 2384 | 0.230 |
Why?
|
Administration, Oral | 11 | 2019 | 3913 | 0.230 |
Why?
|
Erythropoietin | 2 | 2005 | 724 | 0.230 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 2 | 2014 | 1377 | 0.230 |
Why?
|
Loss of Heterozygosity | 3 | 2016 | 678 | 0.220 |
Why?
|
Patient Compliance | 4 | 2012 | 2680 | 0.220 |
Why?
|
Chromans | 1 | 2003 | 122 | 0.220 |
Why?
|
Patient Selection | 11 | 2020 | 4214 | 0.220 |
Why?
|
Arthralgia | 1 | 2007 | 456 | 0.220 |
Why?
|
Benzamides | 4 | 2020 | 1378 | 0.220 |
Why?
|
Cytarabine | 1 | 2005 | 684 | 0.220 |
Why?
|
PTEN Phosphohydrolase | 3 | 2020 | 1144 | 0.220 |
Why?
|
Anxiety | 8 | 2015 | 4279 | 0.220 |
Why?
|
Survival | 2 | 2003 | 162 | 0.220 |
Why?
|
Patient Satisfaction | 6 | 2013 | 3391 | 0.220 |
Why?
|
Insurance, Health | 2 | 2012 | 2493 | 0.220 |
Why?
|
Gene Expression Profiling | 14 | 2021 | 9410 | 0.210 |
Why?
|
DNA Copy Number Variations | 5 | 2021 | 1940 | 0.210 |
Why?
|
Phosphatidylinositol 3-Kinases | 6 | 2022 | 2938 | 0.210 |
Why?
|
Sarcoidosis | 1 | 2007 | 503 | 0.210 |
Why?
|
Myelodysplastic Syndromes | 3 | 2016 | 1351 | 0.210 |
Why?
|
Vascular Endothelial Growth Factor A | 5 | 2020 | 3502 | 0.200 |
Why?
|
Ethics, Clinical | 1 | 2002 | 99 | 0.200 |
Why?
|
Socioeconomic Factors | 9 | 2020 | 7770 | 0.200 |
Why?
|
Anemia | 3 | 2007 | 1499 | 0.200 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2020 | 250 | 0.200 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2005 | 902 | 0.200 |
Why?
|
Male | 54 | 2023 | 349538 | 0.200 |
Why?
|
Estradiol | 4 | 2019 | 2021 | 0.200 |
Why?
|
Markov Chains | 7 | 2011 | 969 | 0.200 |
Why?
|
Germ-Line Mutation | 3 | 2021 | 1786 | 0.200 |
Why?
|
Weight Gain | 6 | 2010 | 2282 | 0.200 |
Why?
|
Consensus | 3 | 2020 | 2935 | 0.200 |
Why?
|
Continuity of Patient Care | 2 | 2005 | 1048 | 0.200 |
Why?
|
Methotrexate | 10 | 2019 | 1720 | 0.190 |
Why?
|
Obesity | 2 | 2021 | 12705 | 0.190 |
Why?
|
Fibroblast Growth Factor 3 | 1 | 2020 | 17 | 0.190 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2009 | 1659 | 0.190 |
Why?
|
Cytochrome P-450 CYP2D6 | 2 | 2013 | 106 | 0.190 |
Why?
|
Attitude to Health | 4 | 2005 | 2051 | 0.190 |
Why?
|
Risk Assessment | 20 | 2021 | 23320 | 0.190 |
Why?
|
Perception | 4 | 2013 | 1188 | 0.190 |
Why?
|
Predictive Value of Tests | 15 | 2021 | 15056 | 0.190 |
Why?
|
Spouses | 1 | 2003 | 284 | 0.190 |
Why?
|
Research Design | 5 | 2021 | 5979 | 0.190 |
Why?
|
Pyrazoles | 2 | 2021 | 1970 | 0.180 |
Why?
|
Phenylthiohydantoin | 2 | 2020 | 192 | 0.180 |
Why?
|
Adenocarcinoma | 3 | 2015 | 6347 | 0.180 |
Why?
|
Registries | 6 | 2023 | 8077 | 0.180 |
Why?
|
Patient Advocacy | 2 | 2015 | 353 | 0.180 |
Why?
|
Risk | 7 | 2020 | 9679 | 0.180 |
Why?
|
Receptors, Steroid | 3 | 2020 | 155 | 0.180 |
Why?
|
Patient Care Planning | 1 | 2005 | 921 | 0.180 |
Why?
|
Diarrhea | 3 | 2019 | 1343 | 0.180 |
Why?
|
Inflammatory Breast Neoplasms | 2 | 2019 | 137 | 0.180 |
Why?
|
Recurrence | 6 | 2019 | 8333 | 0.180 |
Why?
|
ATP-Binding Cassette Transporters | 1 | 2003 | 559 | 0.180 |
Why?
|
Thiazolidinediones | 1 | 2003 | 476 | 0.180 |
Why?
|
Heterocyclic Compounds, 3-Ring | 2 | 2019 | 215 | 0.180 |
Why?
|
Fatigue | 6 | 2015 | 1526 | 0.180 |
Why?
|
Clinical Trials, Phase II as Topic | 6 | 2015 | 627 | 0.170 |
Why?
|
Proto-Oncogene Proteins c-cbl | 1 | 2020 | 119 | 0.170 |
Why?
|
Neoplasms, Glandular and Epithelial | 2 | 2014 | 484 | 0.170 |
Why?
|
Antigens, CD20 | 2 | 2011 | 198 | 0.170 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2020 | 187 | 0.170 |
Why?
|
Multivariate Analysis | 14 | 2019 | 12242 | 0.170 |
Why?
|
Life Expectancy | 3 | 2021 | 1183 | 0.170 |
Why?
|
Drug Delivery Systems | 2 | 2008 | 2217 | 0.170 |
Why?
|
Transplantation, Autologous | 3 | 2005 | 2123 | 0.170 |
Why?
|
Recombinant Proteins | 9 | 2010 | 6608 | 0.170 |
Why?
|
Interpersonal Relations | 1 | 2006 | 1423 | 0.170 |
Why?
|
Tegafur | 1 | 1998 | 49 | 0.170 |
Why?
|
Truth Disclosure | 1 | 2003 | 435 | 0.170 |
Why?
|
Pilot Projects | 11 | 2019 | 8297 | 0.160 |
Why?
|
Radiosurgery | 2 | 2021 | 1309 | 0.160 |
Why?
|
Phenotype | 1 | 2016 | 16331 | 0.160 |
Why?
|
Sensory Receptor Cells | 2 | 2014 | 487 | 0.160 |
Why?
|
Multicenter Studies as Topic | 4 | 2013 | 1661 | 0.160 |
Why?
|
Cell Proliferation | 8 | 2021 | 10472 | 0.160 |
Why?
|
Complementary Therapies | 1 | 2002 | 484 | 0.160 |
Why?
|
Pyrimidinones | 1 | 2020 | 370 | 0.160 |
Why?
|
Amifostine | 3 | 2003 | 41 | 0.160 |
Why?
|
Janus Kinase 2 | 1 | 2021 | 527 | 0.160 |
Why?
|
Axilla | 7 | 2017 | 588 | 0.160 |
Why?
|
Indoles | 1 | 2006 | 1834 | 0.160 |
Why?
|
Endometrial Neoplasms | 1 | 2007 | 1351 | 0.160 |
Why?
|
Patient Education as Topic | 7 | 2012 | 2275 | 0.150 |
Why?
|
Pathology, Surgical | 2 | 2009 | 155 | 0.150 |
Why?
|
Poisson Distribution | 1 | 2019 | 512 | 0.150 |
Why?
|
Retrospective Studies | 33 | 2023 | 77098 | 0.150 |
Why?
|
Salvage Therapy | 5 | 2016 | 1269 | 0.150 |
Why?
|
Body Image | 2 | 2012 | 609 | 0.150 |
Why?
|
Uracil | 1 | 1998 | 164 | 0.150 |
Why?
|
Meningeal Neoplasms | 2 | 2004 | 1241 | 0.150 |
Why?
|
Angiogenesis Inhibitors | 3 | 2016 | 2038 | 0.150 |
Why?
|
Integrative Medicine | 1 | 2018 | 87 | 0.150 |
Why?
|
Epirubicin | 3 | 2013 | 80 | 0.150 |
Why?
|
Research Support as Topic | 3 | 2012 | 704 | 0.140 |
Why?
|
Quality of Health Care | 3 | 2009 | 4369 | 0.140 |
Why?
|
Evidence-Based Medicine | 7 | 2018 | 3611 | 0.140 |
Why?
|
Leukemia, Myeloid | 1 | 2020 | 705 | 0.140 |
Why?
|
Chi-Square Distribution | 2 | 2016 | 3510 | 0.140 |
Why?
|
Silicones | 2 | 1996 | 248 | 0.140 |
Why?
|
Camptothecin | 2 | 2023 | 572 | 0.140 |
Why?
|
Patients | 1 | 2003 | 892 | 0.140 |
Why?
|
Focus Groups | 2 | 2000 | 1320 | 0.140 |
Why?
|
fms-Like Tyrosine Kinase 3 | 1 | 2020 | 491 | 0.140 |
Why?
|
Primary Ovarian Insufficiency | 2 | 2011 | 115 | 0.140 |
Why?
|
Basal Metabolism | 1 | 1997 | 168 | 0.140 |
Why?
|
Cell Line, Tumor | 12 | 2020 | 16665 | 0.140 |
Why?
|
Fluorodeoxyglucose F18 | 4 | 2021 | 2013 | 0.140 |
Why?
|
Communication | 2 | 2008 | 3728 | 0.140 |
Why?
|
Proto-Oncogene Proteins c-akt | 3 | 2020 | 2502 | 0.140 |
Why?
|
Immunohistochemistry | 10 | 2021 | 11363 | 0.140 |
Why?
|
Allelic Imbalance | 1 | 2016 | 77 | 0.130 |
Why?
|
Drug Therapy | 1 | 1999 | 497 | 0.130 |
Why?
|
Heart Diseases | 5 | 2010 | 2789 | 0.130 |
Why?
|
Cell Cycle Proteins | 4 | 2020 | 3444 | 0.130 |
Why?
|
Attitude | 1 | 2020 | 772 | 0.130 |
Why?
|
Small Molecule Libraries | 1 | 2021 | 721 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-met | 2 | 2016 | 578 | 0.130 |
Why?
|
Hospitals | 1 | 2009 | 3937 | 0.130 |
Why?
|
Immunoconjugates | 1 | 2023 | 897 | 0.130 |
Why?
|
Testicular Neoplasms | 1 | 2021 | 761 | 0.130 |
Why?
|
Adolescent | 19 | 2021 | 85649 | 0.130 |
Why?
|
Myeloproliferative Disorders | 1 | 2021 | 603 | 0.130 |
Why?
|
Europe | 3 | 2018 | 3339 | 0.130 |
Why?
|
Pneumocystis carinii | 1 | 2015 | 74 | 0.130 |
Why?
|
Women's Health | 3 | 2012 | 2034 | 0.130 |
Why?
|
Pyrrolidinones | 1 | 2015 | 117 | 0.130 |
Why?
|
High-Throughput Nucleotide Sequencing | 5 | 2020 | 3585 | 0.130 |
Why?
|
Research | 3 | 2013 | 1999 | 0.120 |
Why?
|
Decision Support Techniques | 6 | 2008 | 1952 | 0.120 |
Why?
|
Body Height | 1 | 2021 | 1574 | 0.120 |
Why?
|
Opportunistic Infections | 2 | 2015 | 389 | 0.120 |
Why?
|
Prescription Fees | 1 | 2015 | 146 | 0.120 |
Why?
|
Nurses | 1 | 2004 | 2459 | 0.120 |
Why?
|
Immunomodulation | 1 | 2018 | 540 | 0.120 |
Why?
|
Disease Susceptibility | 2 | 2018 | 1780 | 0.120 |
Why?
|
Reproductive History | 1 | 2015 | 209 | 0.120 |
Why?
|
Treatment Failure | 4 | 2014 | 2615 | 0.120 |
Why?
|
Medical History Taking | 2 | 1998 | 783 | 0.120 |
Why?
|
Tretinoin | 1 | 1997 | 516 | 0.120 |
Why?
|
Receptors, Androgen | 2 | 2018 | 1057 | 0.120 |
Why?
|
Vascular Endothelial Growth Factor Receptor-2 | 1 | 2016 | 544 | 0.120 |
Why?
|
Platinum | 3 | 2021 | 232 | 0.120 |
Why?
|
Odds Ratio | 9 | 2016 | 9846 | 0.120 |
Why?
|
Azepines | 1 | 2016 | 336 | 0.120 |
Why?
|
Endocrine System | 1 | 2014 | 113 | 0.110 |
Why?
|
Transcription Factors | 5 | 2022 | 12164 | 0.110 |
Why?
|
Family | 4 | 2002 | 3144 | 0.110 |
Why?
|
Inflammation | 2 | 2012 | 10578 | 0.110 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 2 | 2013 | 552 | 0.110 |
Why?
|
Hormones | 4 | 2022 | 884 | 0.110 |
Why?
|
Insulin | 1 | 2008 | 6575 | 0.110 |
Why?
|
Liposomes | 5 | 2004 | 758 | 0.110 |
Why?
|
Telemedicine | 1 | 2010 | 2853 | 0.110 |
Why?
|
Drug Synergism | 3 | 2010 | 1791 | 0.110 |
Why?
|
Tumor Burden | 5 | 2019 | 1905 | 0.110 |
Why?
|
Multiprotein Complexes | 2 | 2016 | 1119 | 0.110 |
Why?
|
Quinoxalines | 1 | 2014 | 288 | 0.110 |
Why?
|
Neovascularization, Pathologic | 3 | 2015 | 2633 | 0.110 |
Why?
|
Gene Expression | 2 | 2016 | 7790 | 0.110 |
Why?
|
Alleles | 3 | 2018 | 6931 | 0.110 |
Why?
|
Lymphoma, T-Cell, Peripheral | 1 | 2014 | 134 | 0.110 |
Why?
|
Comorbidity | 9 | 2015 | 10372 | 0.110 |
Why?
|
Self-Help Groups | 1 | 2014 | 187 | 0.110 |
Why?
|
Chromatin | 3 | 2022 | 2917 | 0.110 |
Why?
|
Xenograft Model Antitumor Assays | 5 | 2020 | 3557 | 0.110 |
Why?
|
Oligonucleotide Array Sequence Analysis | 3 | 2011 | 3920 | 0.110 |
Why?
|
Portugal | 1 | 2012 | 87 | 0.110 |
Why?
|
Congresses as Topic | 4 | 2011 | 764 | 0.100 |
Why?
|
Delayed Diagnosis | 2 | 2013 | 438 | 0.100 |
Why?
|
TOR Serine-Threonine Kinases | 3 | 2016 | 2107 | 0.100 |
Why?
|
Fusion Proteins, bcr-abl | 1 | 2014 | 433 | 0.100 |
Why?
|
Patient Preference | 2 | 2017 | 886 | 0.100 |
Why?
|
Immunotoxins | 1 | 2012 | 179 | 0.100 |
Why?
|
Carmustine | 3 | 2005 | 137 | 0.100 |
Why?
|
Mass Screening | 4 | 2021 | 5238 | 0.100 |
Why?
|
Radiation Oncology | 1 | 2018 | 554 | 0.100 |
Why?
|
DNA Repair | 2 | 2018 | 2042 | 0.100 |
Why?
|
Stroke Volume | 3 | 2016 | 4983 | 0.100 |
Why?
|
Medicare | 9 | 2018 | 6532 | 0.100 |
Why?
|
Drug Substitution | 1 | 2014 | 281 | 0.100 |
Why?
|
Cancer Care Facilities | 2 | 2020 | 401 | 0.100 |
Why?
|
Standard of Care | 1 | 2015 | 562 | 0.100 |
Why?
|
Mesna | 2 | 2002 | 66 | 0.100 |
Why?
|
Tissue Donors | 1 | 2020 | 2205 | 0.100 |
Why?
|
Societies | 1 | 2012 | 104 | 0.100 |
Why?
|
Razoxane | 2 | 2002 | 44 | 0.100 |
Why?
|
Physicians | 3 | 2015 | 4554 | 0.100 |
Why?
|
MAP Kinase Signaling System | 2 | 2015 | 1525 | 0.100 |
Why?
|
Nausea | 3 | 2013 | 665 | 0.100 |
Why?
|
Cranial Irradiation | 1 | 2014 | 401 | 0.100 |
Why?
|
Topotecan | 1 | 2011 | 138 | 0.100 |
Why?
|
Environment Design | 1 | 2013 | 178 | 0.100 |
Why?
|
Regression Analysis | 4 | 2014 | 6452 | 0.100 |
Why?
|
Telephone | 2 | 2014 | 617 | 0.100 |
Why?
|
Physician-Patient Relations | 5 | 2011 | 3215 | 0.100 |
Why?
|
Incidence | 9 | 2016 | 20928 | 0.100 |
Why?
|
Radiation-Protective Agents | 2 | 2002 | 89 | 0.100 |
Why?
|
Sleep Disorders, Intrinsic | 1 | 2010 | 15 | 0.100 |
Why?
|
Antigens, Neoplasm | 2 | 2009 | 1983 | 0.090 |
Why?
|
Longitudinal Studies | 5 | 2014 | 13921 | 0.090 |
Why?
|
Prednisone | 4 | 2014 | 1567 | 0.090 |
Why?
|
International Cooperation | 3 | 2012 | 1421 | 0.090 |
Why?
|
Benzothiazoles | 1 | 2011 | 247 | 0.090 |
Why?
|
Early Detection of Cancer | 6 | 2021 | 3070 | 0.090 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2016 | 986 | 0.090 |
Why?
|
Expert Testimony | 3 | 2019 | 356 | 0.090 |
Why?
|
Piperidines | 2 | 2012 | 1602 | 0.090 |
Why?
|
Gene Amplification | 3 | 2010 | 1062 | 0.090 |
Why?
|
Advisory Committees | 3 | 2009 | 773 | 0.090 |
Why?
|
Phenylurea Compounds | 1 | 2013 | 526 | 0.090 |
Why?
|
Inservice Training | 1 | 2013 | 392 | 0.090 |
Why?
|
Cyclohexanols | 1 | 2010 | 127 | 0.090 |
Why?
|
Sexual Behavior | 3 | 2012 | 2050 | 0.090 |
Why?
|
Megestrol Acetate | 2 | 2000 | 18 | 0.090 |
Why?
|
Protective Agents | 2 | 2002 | 156 | 0.090 |
Why?
|
Telomere | 1 | 2016 | 909 | 0.090 |
Why?
|
Ovariectomy | 3 | 2014 | 660 | 0.090 |
Why?
|
Factor V | 1 | 2010 | 174 | 0.090 |
Why?
|
Genotype | 4 | 2019 | 12946 | 0.090 |
Why?
|
Signal Transduction | 9 | 2021 | 23387 | 0.090 |
Why?
|
Data Collection | 6 | 2013 | 3339 | 0.090 |
Why?
|
Soft Tissue Neoplasms | 1 | 2019 | 1361 | 0.090 |
Why?
|
Phosphorylation | 5 | 2021 | 8436 | 0.090 |
Why?
|
Massachusetts | 3 | 2012 | 8662 | 0.090 |
Why?
|
Intention to Treat Analysis | 2 | 2022 | 425 | 0.080 |
Why?
|
Body Composition | 3 | 2008 | 2400 | 0.080 |
Why?
|
Drug Costs | 2 | 2015 | 1104 | 0.080 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2014 | 689 | 0.080 |
Why?
|
Epithelial Cells | 1 | 2021 | 3678 | 0.080 |
Why?
|
Polymorphism, Single Nucleotide | 6 | 2020 | 15494 | 0.080 |
Why?
|
Macrophages | 2 | 2021 | 5655 | 0.080 |
Why?
|
DNA Topoisomerases, Type II | 1 | 2009 | 121 | 0.080 |
Why?
|
Bone Neoplasms | 2 | 2019 | 2522 | 0.080 |
Why?
|
Feasibility Studies | 7 | 2019 | 5062 | 0.080 |
Why?
|
Bone Density | 2 | 2012 | 3469 | 0.080 |
Why?
|
Financing, Government | 2 | 2009 | 468 | 0.080 |
Why?
|
Protein Structure, Tertiary | 1 | 2016 | 3847 | 0.080 |
Why?
|
Reference Values | 1 | 2016 | 4982 | 0.080 |
Why?
|
Ambulatory Care | 3 | 2007 | 2706 | 0.080 |
Why?
|
California | 1 | 2012 | 1400 | 0.080 |
Why?
|
Selective Estrogen Receptor Modulators | 4 | 2010 | 129 | 0.080 |
Why?
|
Health Status Disparities | 4 | 2015 | 1794 | 0.080 |
Why?
|
Cytoskeletal Proteins | 1 | 2014 | 1363 | 0.080 |
Why?
|
DNA Damage | 1 | 2018 | 2423 | 0.080 |
Why?
|
Hot Flashes | 1 | 2010 | 316 | 0.080 |
Why?
|
Therapies, Investigational | 1 | 2008 | 111 | 0.080 |
Why?
|
Liver Neoplasms | 4 | 2018 | 4249 | 0.080 |
Why?
|
Heterozygote | 5 | 2015 | 2790 | 0.080 |
Why?
|
Primary Health Care | 4 | 2007 | 4551 | 0.080 |
Why?
|
Prevalence | 7 | 2020 | 15194 | 0.080 |
Why?
|
In Situ Hybridization, Fluorescence | 6 | 2016 | 2638 | 0.080 |
Why?
|
Urogenital Neoplasms | 1 | 2008 | 135 | 0.070 |
Why?
|
Animals | 19 | 2022 | 168561 | 0.070 |
Why?
|
Interferon Regulatory Factors | 1 | 2009 | 270 | 0.070 |
Why?
|
Reality Therapy | 1 | 2006 | 5 | 0.070 |
Why?
|
Resistance Training | 1 | 2009 | 164 | 0.070 |
Why?
|
Thrombocytopenia | 2 | 2014 | 1171 | 0.070 |
Why?
|
Adaptor Proteins, Signal Transducing | 2 | 2016 | 2915 | 0.070 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2008 | 281 | 0.070 |
Why?
|
Educational Status | 4 | 2012 | 2533 | 0.070 |
Why?
|
Ventricular Dysfunction, Left | 2 | 2016 | 2059 | 0.070 |
Why?
|
Troponin I | 1 | 2011 | 619 | 0.070 |
Why?
|
Waist-Hip Ratio | 1 | 2008 | 517 | 0.070 |
Why?
|
Multifactorial Inheritance | 1 | 2014 | 1190 | 0.070 |
Why?
|
Ventricular Function, Left | 3 | 2016 | 3656 | 0.070 |
Why?
|
Magnetic Resonance Imaging | 7 | 2020 | 35342 | 0.070 |
Why?
|
Benzimidazoles | 2 | 2021 | 848 | 0.070 |
Why?
|
Diphosphonates | 1 | 2011 | 625 | 0.070 |
Why?
|
Lymphopenia | 1 | 2008 | 285 | 0.070 |
Why?
|
Prostheses and Implants | 1 | 1993 | 1385 | 0.070 |
Why?
|
Axons | 1 | 2014 | 1681 | 0.070 |
Why?
|
Fertility Agents | 1 | 2005 | 11 | 0.070 |
Why?
|
Blood Cell Count | 1 | 2006 | 402 | 0.070 |
Why?
|
Anthropometry | 1 | 2010 | 1350 | 0.070 |
Why?
|
Leukemia | 2 | 2006 | 1507 | 0.070 |
Why?
|
Ligands | 2 | 2022 | 3293 | 0.070 |
Why?
|
Chromosomes, Human, Pair 4 | 1 | 2006 | 374 | 0.060 |
Why?
|
Genetic Heterogeneity | 2 | 2021 | 732 | 0.060 |
Why?
|
Sulfonamides | 1 | 2014 | 1932 | 0.060 |
Why?
|
Preventive Medicine | 1 | 2007 | 263 | 0.060 |
Why?
|
Antiemetics | 1 | 2006 | 176 | 0.060 |
Why?
|
Chromosomes, Human, Pair 11 | 1 | 2006 | 417 | 0.060 |
Why?
|
Drug Utilization | 2 | 2002 | 1181 | 0.060 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2015 | 2948 | 0.060 |
Why?
|
Neoplasm Transplantation | 2 | 2021 | 2085 | 0.060 |
Why?
|
Daunorubicin | 1 | 2004 | 149 | 0.060 |
Why?
|
Health Services Accessibility | 4 | 2020 | 5133 | 0.060 |
Why?
|
Stress, Psychological | 3 | 2012 | 4229 | 0.060 |
Why?
|
Imidazoles | 1 | 2011 | 1205 | 0.060 |
Why?
|
Lung Neoplasms | 6 | 2018 | 13019 | 0.060 |
Why?
|
Multiple Myeloma | 1 | 2022 | 5169 | 0.060 |
Why?
|
Comprehension | 2 | 2007 | 608 | 0.060 |
Why?
|
Apoptosis | 2 | 2021 | 9715 | 0.060 |
Why?
|
Immunotherapy | 1 | 2020 | 4414 | 0.060 |
Why?
|
Social Class | 2 | 2010 | 1995 | 0.060 |
Why?
|
Depression | 5 | 2012 | 7733 | 0.060 |
Why?
|
Pandemics | 2 | 2021 | 8328 | 0.060 |
Why?
|
North Carolina | 2 | 2002 | 311 | 0.060 |
Why?
|
Radiopharmaceuticals | 3 | 2021 | 2658 | 0.060 |
Why?
|
Genome, Human | 4 | 2021 | 4420 | 0.060 |
Why?
|
Mitotic Index | 2 | 2017 | 172 | 0.060 |
Why?
|
Specimen Handling | 1 | 2009 | 692 | 0.060 |
Why?
|
Genetic Markers | 4 | 1999 | 2633 | 0.060 |
Why?
|
Social Adjustment | 1 | 2006 | 630 | 0.060 |
Why?
|
Forecasting | 3 | 2008 | 2948 | 0.060 |
Why?
|
Nurse-Patient Relations | 1 | 2004 | 101 | 0.060 |
Why?
|
Sirolimus | 1 | 2011 | 1562 | 0.060 |
Why?
|
Immunity, Innate | 1 | 2016 | 2956 | 0.060 |
Why?
|
Antigen Presentation | 2 | 2021 | 1284 | 0.060 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2011 | 1379 | 0.060 |
Why?
|
Thromboembolism | 1 | 2010 | 983 | 0.060 |
Why?
|
Cross-Over Studies | 3 | 2020 | 2030 | 0.060 |
Why?
|
Hydroxyurea | 1 | 2005 | 290 | 0.060 |
Why?
|
Anti-Inflammatory Agents | 2 | 2006 | 1788 | 0.060 |
Why?
|
Nanoparticles | 1 | 2015 | 1902 | 0.060 |
Why?
|
Bone Density Conservation Agents | 1 | 2011 | 774 | 0.060 |
Why?
|
Alopecia | 1 | 2007 | 381 | 0.060 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2005 | 358 | 0.060 |
Why?
|
Positron-Emission Tomography | 4 | 2017 | 6259 | 0.060 |
Why?
|
Models, Organizational | 1 | 2007 | 574 | 0.060 |
Why?
|
Genital Neoplasms, Female | 1 | 2008 | 516 | 0.060 |
Why?
|
Xerostomia | 1 | 2003 | 95 | 0.060 |
Why?
|
Unnecessary Procedures | 1 | 2007 | 431 | 0.060 |
Why?
|
Fever | 2 | 2011 | 1612 | 0.060 |
Why?
|
Emigrants and Immigrants | 1 | 2009 | 519 | 0.060 |
Why?
|
Ovulation Induction | 1 | 2005 | 274 | 0.060 |
Why?
|
Nuclear Proteins | 2 | 2016 | 5851 | 0.060 |
Why?
|
Gonadotropin-Releasing Hormone | 2 | 2014 | 1185 | 0.050 |
Why?
|
Mice | 10 | 2022 | 81045 | 0.050 |
Why?
|
Tetrahydronaphthalenes | 1 | 2003 | 89 | 0.050 |
Why?
|
DNA Mutational Analysis | 3 | 2016 | 4187 | 0.050 |
Why?
|
Constipation | 1 | 2007 | 546 | 0.050 |
Why?
|
Anticarcinogenic Agents | 1 | 2004 | 253 | 0.050 |
Why?
|
Health Care Costs | 2 | 2008 | 3203 | 0.050 |
Why?
|
Drug Therapy, Combination | 4 | 2016 | 6483 | 0.050 |
Why?
|
Diagnostic Imaging | 1 | 2017 | 3507 | 0.050 |
Why?
|
Cryopreservation | 1 | 2007 | 664 | 0.050 |
Why?
|
Hypnotics and Sedatives | 1 | 2010 | 1158 | 0.050 |
Why?
|
Quality-Adjusted Life Years | 4 | 2007 | 1679 | 0.050 |
Why?
|
Parity | 2 | 2015 | 929 | 0.050 |
Why?
|
Vincristine | 3 | 2014 | 1036 | 0.050 |
Why?
|
Blood Platelets | 1 | 2012 | 2506 | 0.050 |
Why?
|
Patient Rights | 1 | 2002 | 125 | 0.050 |
Why?
|
Demography | 1 | 2006 | 1650 | 0.050 |
Why?
|
Health Services Research | 1 | 2009 | 1834 | 0.050 |
Why?
|
Tomography, X-Ray Computed | 3 | 2016 | 20086 | 0.050 |
Why?
|
Topoisomerase I Inhibitors | 1 | 2001 | 65 | 0.050 |
Why?
|
Insurance Coverage | 2 | 2010 | 1895 | 0.050 |
Why?
|
Drug Interactions | 2 | 2009 | 1458 | 0.050 |
Why?
|
Thiotepa | 1 | 2001 | 66 | 0.050 |
Why?
|
Genomic Instability | 2 | 2016 | 695 | 0.050 |
Why?
|
Analysis of Variance | 4 | 2020 | 6365 | 0.050 |
Why?
|
Diagnostic Tests, Routine | 1 | 2007 | 783 | 0.050 |
Why?
|
Leptin | 1 | 2009 | 1593 | 0.050 |
Why?
|
Biomarkers, Pharmacological | 2 | 2012 | 162 | 0.050 |
Why?
|
Accidents, Traffic | 1 | 2006 | 819 | 0.050 |
Why?
|
Drug Industry | 1 | 2007 | 744 | 0.050 |
Why?
|
Progestins | 1 | 2003 | 303 | 0.050 |
Why?
|
Premedication | 1 | 2021 | 257 | 0.050 |
Why?
|
Erythrocyte Transfusion | 1 | 2005 | 565 | 0.050 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2008 | 987 | 0.050 |
Why?
|
Chelating Agents | 1 | 2002 | 380 | 0.050 |
Why?
|
Gadolinium | 1 | 2006 | 951 | 0.050 |
Why?
|
Magnetic Resonance Angiography | 1 | 2007 | 1440 | 0.050 |
Why?
|
Models, Biological | 3 | 2018 | 9581 | 0.050 |
Why?
|
Algorithms | 5 | 2012 | 13853 | 0.050 |
Why?
|
Organizational Policy | 1 | 2003 | 427 | 0.050 |
Why?
|
Genetic Counseling | 2 | 2002 | 600 | 0.050 |
Why?
|
Translocation, Genetic | 1 | 2006 | 1417 | 0.050 |
Why?
|
Hospice Care | 1 | 2007 | 671 | 0.050 |
Why?
|
Cross-Sectional Studies | 7 | 2013 | 24913 | 0.050 |
Why?
|
Social Support | 2 | 2008 | 2117 | 0.050 |
Why?
|
Mammaplasty | 3 | 2013 | 1195 | 0.040 |
Why?
|
Genome-Wide Association Study | 3 | 2015 | 12220 | 0.040 |
Why?
|
Hormone Replacement Therapy | 2 | 2007 | 744 | 0.040 |
Why?
|
Mice, Transgenic | 3 | 2018 | 9735 | 0.040 |
Why?
|
Residence Characteristics | 1 | 2009 | 2049 | 0.040 |
Why?
|
Retinoblastoma Binding Proteins | 1 | 2020 | 97 | 0.040 |
Why?
|
Polyesters | 1 | 2001 | 363 | 0.040 |
Why?
|
Treatment Refusal | 1 | 2003 | 416 | 0.040 |
Why?
|
Heart Failure | 4 | 2013 | 10856 | 0.040 |
Why?
|
User-Computer Interface | 1 | 2006 | 1426 | 0.040 |
Why?
|
Neuroendocrine Tumors | 1 | 2005 | 594 | 0.040 |
Why?
|
Publishing | 1 | 2007 | 833 | 0.040 |
Why?
|
Disease Management | 3 | 2015 | 2450 | 0.040 |
Why?
|
Fractures, Bone | 1 | 2011 | 1945 | 0.040 |
Why?
|
Dexamethasone | 1 | 2006 | 1949 | 0.040 |
Why?
|
Mitoxantrone | 1 | 1999 | 149 | 0.040 |
Why?
|
Proteomics | 3 | 2020 | 3618 | 0.040 |
Why?
|
Organoplatinum Compounds | 1 | 2001 | 408 | 0.040 |
Why?
|
Drug Monitoring | 2 | 2019 | 956 | 0.040 |
Why?
|
C-Reactive Protein | 1 | 2011 | 3766 | 0.040 |
Why?
|
Anti-Infective Agents | 1 | 2006 | 971 | 0.040 |
Why?
|
Hematologic Diseases | 2 | 2001 | 498 | 0.040 |
Why?
|
Early Diagnosis | 2 | 2017 | 1184 | 0.040 |
Why?
|
Staurosporine | 1 | 2020 | 251 | 0.040 |
Why?
|
Nutrition Surveys | 1 | 2005 | 1656 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2022 | 704 | 0.040 |
Why?
|
Calcinosis | 1 | 2007 | 1497 | 0.040 |
Why?
|
Aminoglycosides | 1 | 1999 | 161 | 0.040 |
Why?
|
Blood Donors | 1 | 2020 | 355 | 0.040 |
Why?
|
Blood-Brain Barrier | 2 | 2018 | 1015 | 0.040 |
Why?
|
Epidermal Growth Factor | 1 | 2021 | 709 | 0.040 |
Why?
|
Affect | 1 | 2006 | 1473 | 0.040 |
Why?
|
Chromosome Mapping | 2 | 1998 | 4742 | 0.040 |
Why?
|
Mind-Body Therapies | 1 | 2021 | 247 | 0.040 |
Why?
|
Reproducibility of Results | 4 | 2021 | 19862 | 0.040 |
Why?
|
Academies and Institutes | 1 | 2020 | 317 | 0.040 |
Why?
|
Vesicular Transport Proteins | 1 | 2021 | 377 | 0.040 |
Why?
|
Community-Based Participatory Research | 1 | 2020 | 214 | 0.040 |
Why?
|
Thiophenes | 1 | 2003 | 590 | 0.040 |
Why?
|
DNA-Binding Proteins | 3 | 2012 | 9639 | 0.040 |
Why?
|
Hematinics | 1 | 2001 | 281 | 0.040 |
Why?
|
Pain | 4 | 2011 | 4961 | 0.040 |
Why?
|
Clinical Trials, Phase I as Topic | 2 | 2013 | 319 | 0.040 |
Why?
|
Drug Hypersensitivity | 1 | 2007 | 883 | 0.040 |
Why?
|
History, 20th Century | 1 | 2006 | 2739 | 0.040 |
Why?
|
Hypesthesia | 1 | 1998 | 110 | 0.040 |
Why?
|
Osteoporosis | 2 | 2014 | 1581 | 0.040 |
Why?
|
Preventive Health Services | 1 | 2003 | 575 | 0.040 |
Why?
|
Energy Metabolism | 2 | 2001 | 2896 | 0.040 |
Why?
|
Cognition Disorders | 2 | 2004 | 4030 | 0.040 |
Why?
|
Delivery of Health Care | 3 | 2021 | 5304 | 0.040 |
Why?
|
Melphalan | 2 | 1999 | 431 | 0.040 |
Why?
|
Analgesia, Patient-Controlled | 1 | 1998 | 109 | 0.040 |
Why?
|
United States Food and Drug Administration | 2 | 2020 | 1581 | 0.040 |
Why?
|
Health Care Surveys | 2 | 2011 | 2451 | 0.040 |
Why?
|
Confidence Intervals | 2 | 2014 | 2970 | 0.040 |
Why?
|
Rats, Inbred Strains | 2 | 1995 | 2191 | 0.040 |
Why?
|
Chromosomes, Human, Pair 18 | 1 | 2018 | 245 | 0.040 |
Why?
|
Sarcoma | 1 | 2008 | 1895 | 0.040 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2006 | 1515 | 0.040 |
Why?
|
Austria | 1 | 2017 | 201 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2022 | 4438 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor D | 1 | 2016 | 63 | 0.040 |
Why?
|
Evaluation Studies as Topic | 1 | 2019 | 1676 | 0.040 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 2018 | 366 | 0.040 |
Why?
|
Hematologic Neoplasms | 1 | 2008 | 1820 | 0.040 |
Why?
|
Sexuality | 1 | 1998 | 174 | 0.030 |
Why?
|
Capsules | 2 | 2013 | 199 | 0.030 |
Why?
|
Interleukin-6 | 1 | 2006 | 3199 | 0.030 |
Why?
|
Mediator Complex Subunit 1 | 1 | 2016 | 29 | 0.030 |
Why?
|
Postoperative Complications | 3 | 2013 | 15244 | 0.030 |
Why?
|
Eukaryotic Initiation Factors | 1 | 2016 | 92 | 0.030 |
Why?
|
Cell Count | 1 | 2020 | 1831 | 0.030 |
Why?
|
Boston | 2 | 2007 | 9305 | 0.030 |
Why?
|
Drug Approval | 1 | 2022 | 740 | 0.030 |
Why?
|
RNA, Double-Stranded | 1 | 2017 | 289 | 0.030 |
Why?
|
Body Temperature Regulation | 1 | 1997 | 252 | 0.030 |
Why?
|
Life Tables | 1 | 1996 | 370 | 0.030 |
Why?
|
Cognition | 1 | 2013 | 6722 | 0.030 |
Why?
|
Sensitivity and Specificity | 2 | 2009 | 14720 | 0.030 |
Why?
|
Receptors, Angiotensin | 1 | 1995 | 142 | 0.030 |
Why?
|
Knowledge | 1 | 1997 | 179 | 0.030 |
Why?
|
Phosphoserine | 1 | 2016 | 206 | 0.030 |
Why?
|
ROC Curve | 1 | 2003 | 3528 | 0.030 |
Why?
|
Genes, p53 | 2 | 2010 | 755 | 0.030 |
Why?
|
Casein Kinase II | 1 | 2016 | 128 | 0.030 |
Why?
|
Cost of Illness | 1 | 2005 | 1852 | 0.030 |
Why?
|
Infusion Pumps, Implantable | 1 | 1996 | 156 | 0.030 |
Why?
|
Hypertension | 2 | 2014 | 8455 | 0.030 |
Why?
|
Tissue Distribution | 1 | 2019 | 2335 | 0.030 |
Why?
|
Eukaryotic Initiation Factor-3 | 1 | 2015 | 49 | 0.030 |
Why?
|
Thalidomide | 1 | 2000 | 888 | 0.030 |
Why?
|
Craniotomy | 1 | 2019 | 729 | 0.030 |
Why?
|
Polymorphism, Genetic | 2 | 1995 | 4328 | 0.030 |
Why?
|
Models, Animal | 1 | 2001 | 2170 | 0.030 |
Why?
|
Hematopoietic Stem Cells | 1 | 2007 | 3381 | 0.030 |
Why?
|
Heart | 1 | 2008 | 4462 | 0.030 |
Why?
|
Sick Role | 2 | 2008 | 237 | 0.030 |
Why?
|
Binding, Competitive | 1 | 2016 | 1159 | 0.030 |
Why?
|
Infertility, Female | 1 | 2000 | 784 | 0.030 |
Why?
|
Jews | 1 | 2016 | 385 | 0.030 |
Why?
|
Protein Phosphatase 2 | 1 | 2016 | 229 | 0.030 |
Why?
|
Integrin alpha4 | 1 | 2014 | 92 | 0.030 |
Why?
|
Disease Models, Animal | 3 | 2018 | 18006 | 0.030 |
Why?
|
Caspase 3 | 1 | 2016 | 759 | 0.030 |
Why?
|
Genes, Tumor Suppressor | 1 | 1998 | 1097 | 0.030 |
Why?
|
Directive Counseling | 1 | 2015 | 166 | 0.030 |
Why?
|
Interferons | 1 | 2017 | 704 | 0.030 |
Why?
|
Viruses | 1 | 2017 | 374 | 0.030 |
Why?
|
RNA Interference | 1 | 2022 | 2890 | 0.030 |
Why?
|
Blood Glucose | 1 | 2008 | 6249 | 0.030 |
Why?
|
Employment | 2 | 2005 | 1124 | 0.030 |
Why?
|
Tumor Cells, Cultured | 1 | 2021 | 6313 | 0.030 |
Why?
|
Health Status | 2 | 2005 | 4030 | 0.030 |
Why?
|
Energy Intake | 2 | 2001 | 2147 | 0.030 |
Why?
|
Feeding Behavior | 1 | 2005 | 3187 | 0.030 |
Why?
|
Clinical Protocols | 2 | 2009 | 1459 | 0.030 |
Why?
|
Eligibility Determination | 1 | 2016 | 403 | 0.030 |
Why?
|
Tablets | 1 | 2013 | 147 | 0.030 |
Why?
|
Receptor, EphA5 | 1 | 2012 | 11 | 0.030 |
Why?
|
Cardiovascular Agents | 1 | 1999 | 848 | 0.030 |
Why?
|
Depressive Disorder | 2 | 2012 | 3748 | 0.030 |
Why?
|
Activities of Daily Living | 2 | 2001 | 2414 | 0.030 |
Why?
|
Medical Records | 1 | 1998 | 1413 | 0.030 |
Why?
|
Tumor Suppressor Proteins | 2 | 2016 | 2842 | 0.030 |
Why?
|
Case-Control Studies | 4 | 2016 | 21719 | 0.030 |
Why?
|
Mammary Neoplasms, Experimental | 1 | 2015 | 520 | 0.030 |
Why?
|
Tissue and Organ Procurement | 1 | 2020 | 890 | 0.030 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 1683 | 0.030 |
Why?
|
Cell Line, Transformed | 1 | 2014 | 898 | 0.030 |
Why?
|
Breast Implants | 1 | 1996 | 378 | 0.030 |
Why?
|
Receptor, erbB-3 | 1 | 2013 | 142 | 0.030 |
Why?
|
Area Under Curve | 1 | 1997 | 1653 | 0.030 |
Why?
|
Angiotensin II | 1 | 1995 | 881 | 0.030 |
Why?
|
Income | 1 | 2021 | 1904 | 0.030 |
Why?
|
Platelet Factor 4 | 1 | 2012 | 129 | 0.030 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2018 | 1372 | 0.030 |
Why?
|
K562 Cells | 1 | 2014 | 632 | 0.030 |
Why?
|
Postoperative Care | 1 | 1999 | 1484 | 0.030 |
Why?
|
RNA | 1 | 2022 | 2747 | 0.030 |
Why?
|
Preoperative Period | 1 | 2014 | 546 | 0.030 |
Why?
|
Diagnosis, Differential | 1 | 2007 | 12958 | 0.030 |
Why?
|
Streptozocin | 1 | 1992 | 193 | 0.030 |
Why?
|
Antigens, CD34 | 1 | 2014 | 657 | 0.030 |
Why?
|
Adjuvants, Immunologic | 1 | 2017 | 1000 | 0.030 |
Why?
|
Drug Eruptions | 1 | 2015 | 295 | 0.030 |
Why?
|
Comprehensive Health Care | 1 | 2013 | 127 | 0.030 |
Why?
|
Age Distribution | 1 | 2018 | 2900 | 0.030 |
Why?
|
Cardiovascular Diseases | 3 | 2004 | 15108 | 0.030 |
Why?
|
Health Behavior | 2 | 2008 | 2630 | 0.030 |
Why?
|
Cooperative Behavior | 2 | 2010 | 1503 | 0.020 |
Why?
|
Vascular Cell Adhesion Molecule-1 | 1 | 2014 | 707 | 0.020 |
Why?
|
Hydrocortisone | 1 | 1999 | 1825 | 0.020 |
Why?
|
Mice, Inbred NOD | 1 | 2015 | 1875 | 0.020 |
Why?
|
Adaptation, Physiological | 1 | 2018 | 1310 | 0.020 |
Why?
|
Chromosome Aberrations | 1 | 2018 | 1811 | 0.020 |
Why?
|
Pregnancy | 2 | 2015 | 29087 | 0.020 |
Why?
|
Nomograms | 1 | 2012 | 224 | 0.020 |
Why?
|
Cell Growth Processes | 1 | 2011 | 400 | 0.020 |
Why?
|
Mice, SCID | 1 | 2016 | 2715 | 0.020 |
Why?
|
Models, Genetic | 1 | 2021 | 3493 | 0.020 |
Why?
|
Severity of Illness Index | 4 | 2015 | 15530 | 0.020 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2020 | 1860 | 0.020 |
Why?
|
Fibroblasts | 1 | 2021 | 4143 | 0.020 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2014 | 651 | 0.020 |
Why?
|
Micro-Electrical-Mechanical Systems | 1 | 2010 | 31 | 0.020 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2008 | 5425 | 0.020 |
Why?
|
Models, Theoretical | 2 | 2006 | 3584 | 0.020 |
Why?
|
Myocardial Infarction | 1 | 2011 | 11690 | 0.020 |
Why?
|
Drug Evaluation | 2 | 2007 | 637 | 0.020 |
Why?
|
Cloning, Molecular | 1 | 1995 | 4322 | 0.020 |
Why?
|
Cardiac Electrophysiology | 1 | 2009 | 48 | 0.020 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2013 | 664 | 0.020 |
Why?
|
Secondary Prevention | 1 | 2016 | 1520 | 0.020 |
Why?
|
Age of Onset | 1 | 2016 | 3266 | 0.020 |
Why?
|
Karnofsky Performance Status | 1 | 2009 | 173 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2018 | 4200 | 0.020 |
Why?
|
DNA, Neoplasm | 1 | 2015 | 1758 | 0.020 |
Why?
|
Mice, Nude | 1 | 2016 | 3689 | 0.020 |
Why?
|
Methyltransferases | 1 | 1992 | 367 | 0.020 |
Why?
|
Economics | 1 | 2010 | 146 | 0.020 |
Why?
|
Cardiomyopathies | 1 | 2001 | 1912 | 0.020 |
Why?
|
Radiotherapy Dosage | 2 | 2006 | 2876 | 0.020 |
Why?
|
Receptors, Cell Surface | 1 | 2018 | 2867 | 0.020 |
Why?
|
Pedigree | 1 | 1997 | 4646 | 0.020 |
Why?
|
Developing Countries | 1 | 2021 | 2789 | 0.020 |
Why?
|
Climacteric | 1 | 2008 | 57 | 0.020 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2006 | 4248 | 0.020 |
Why?
|
Pyrimidines | 1 | 2021 | 2933 | 0.020 |
Why?
|
Bayes Theorem | 1 | 1997 | 2303 | 0.020 |
Why?
|
Stroke | 1 | 2011 | 9963 | 0.020 |
Why?
|
Rats | 4 | 1998 | 24265 | 0.020 |
Why?
|
Case Management | 1 | 2010 | 286 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2015 | 2713 | 0.020 |
Why?
|
Marital Status | 1 | 2010 | 437 | 0.020 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 694 | 0.020 |
Why?
|
Health Surveys | 2 | 2013 | 4030 | 0.020 |
Why?
|
Smoking | 2 | 2010 | 8969 | 0.020 |
Why?
|
Personal Satisfaction | 1 | 2012 | 634 | 0.020 |
Why?
|
Patient-Centered Care | 1 | 1998 | 1436 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2021 | 3679 | 0.020 |
Why?
|
Antineoplastic Protocols | 1 | 2007 | 47 | 0.020 |
Why?
|
Child | 2 | 2008 | 77478 | 0.020 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2014 | 1333 | 0.020 |
Why?
|
Liver | 1 | 2003 | 7470 | 0.020 |
Why?
|
Polyglutamic Acid | 1 | 2007 | 45 | 0.020 |
Why?
|
Motivation | 1 | 1997 | 1968 | 0.020 |
Why?
|
Cell Adhesion | 1 | 2014 | 3139 | 0.020 |
Why?
|
Phosphoproteins | 1 | 2016 | 2440 | 0.020 |
Why?
|
Governing Board | 1 | 2007 | 53 | 0.020 |
Why?
|
Colony-Forming Units Assay | 1 | 2007 | 354 | 0.020 |
Why?
|
Cost-Benefit Analysis | 3 | 2007 | 5385 | 0.020 |
Why?
|
Consent Forms | 1 | 2007 | 53 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2010 | 1799 | 0.020 |
Why?
|
Microfilament Proteins | 1 | 2012 | 1152 | 0.020 |
Why?
|
Escape Reaction | 1 | 2006 | 54 | 0.020 |
Why?
|
Molecular Weight | 1 | 2009 | 2255 | 0.020 |
Why?
|
Prostatic Neoplasms | 2 | 2000 | 11039 | 0.020 |
Why?
|
Freezing | 1 | 2007 | 303 | 0.020 |
Why?
|
Cytokines | 1 | 2021 | 7317 | 0.020 |
Why?
|
Adrenal Cortex Hormones | 1 | 2015 | 1847 | 0.020 |
Why?
|
Ambulatory Care Facilities | 1 | 2013 | 932 | 0.020 |
Why?
|
Fear | 1 | 2015 | 1436 | 0.020 |
Why?
|
Arousal | 1 | 2012 | 1165 | 0.020 |
Why?
|
Organizational Case Studies | 1 | 2007 | 299 | 0.020 |
Why?
|
Gene Dosage | 1 | 2011 | 1251 | 0.020 |
Why?
|
Hospitalization | 2 | 2021 | 10232 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 2 | 2013 | 3014 | 0.020 |
Why?
|
Tocopherols | 1 | 2005 | 42 | 0.020 |
Why?
|
Antibody Specificity | 1 | 2008 | 1094 | 0.020 |
Why?
|
Hyperglycemia | 1 | 2015 | 1368 | 0.020 |
Why?
|
Computational Biology | 1 | 2018 | 3518 | 0.020 |
Why?
|
Cytogenetics | 1 | 2006 | 203 | 0.020 |
Why?
|
Placebos | 1 | 2010 | 1677 | 0.020 |
Why?
|
Habituation, Psychophysiologic | 1 | 2006 | 154 | 0.020 |
Why?
|
Colorectal Neoplasms | 1 | 2005 | 6754 | 0.020 |
Why?
|
Crosses, Genetic | 2 | 1998 | 791 | 0.020 |
Why?
|
Surgical Procedures, Operative | 1 | 2017 | 1873 | 0.020 |
Why?
|
Cell Survival | 1 | 2015 | 5872 | 0.020 |
Why?
|
Teaching Materials | 1 | 2005 | 86 | 0.020 |
Why?
|
Medicaid | 2 | 2012 | 2716 | 0.020 |
Why?
|
Up-Regulation | 1 | 2014 | 4211 | 0.020 |
Why?
|
Radiation Pneumonitis | 1 | 2005 | 104 | 0.020 |
Why?
|
Guideline Adherence | 2 | 2007 | 2266 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2016 | 5519 | 0.020 |
Why?
|
Transcription, Genetic | 2 | 2016 | 7721 | 0.020 |
Why?
|
Quantitative Trait Loci | 1 | 2012 | 2015 | 0.020 |
Why?
|
Canada | 1 | 2010 | 2061 | 0.020 |
Why?
|
Cause of Death | 1 | 2015 | 3571 | 0.020 |
Why?
|
Confusion | 1 | 2006 | 275 | 0.020 |
Why?
|
Linear Models | 2 | 2010 | 5948 | 0.020 |
Why?
|
Cell Line | 1 | 2018 | 15994 | 0.020 |
Why?
|
Spirituality | 1 | 2008 | 405 | 0.020 |
Why?
|
Qualitative Research | 1 | 2013 | 2680 | 0.010 |
Why?
|
Authorship | 1 | 2007 | 271 | 0.010 |
Why?
|
Observer Variation | 1 | 2010 | 2593 | 0.010 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2017 | 2986 | 0.010 |
Why?
|
Immunoglobulin G | 1 | 2015 | 4554 | 0.010 |
Why?
|
Protein Binding | 1 | 2016 | 9387 | 0.010 |
Why?
|
Models, Statistical | 2 | 2010 | 5100 | 0.010 |
Why?
|
Toremifene | 1 | 2003 | 24 | 0.010 |
Why?
|
Brain | 2 | 2020 | 26343 | 0.010 |
Why?
|
Interviews as Topic | 1 | 2010 | 2536 | 0.010 |
Why?
|
Adiponectin | 1 | 2009 | 1099 | 0.010 |
Why?
|
Long-Term Care | 1 | 2007 | 607 | 0.010 |
Why?
|
Genetic Loci | 1 | 2012 | 2572 | 0.010 |
Why?
|
Carrier Proteins | 1 | 2016 | 5019 | 0.010 |
Why?
|
Subtraction Technique | 1 | 2006 | 525 | 0.010 |
Why?
|
New Jersey | 1 | 2003 | 290 | 0.010 |
Why?
|
Office Visits | 1 | 2007 | 598 | 0.010 |
Why?
|
Epigenesis, Genetic | 1 | 2016 | 3639 | 0.010 |
Why?
|
Hodgkin Disease | 1 | 1990 | 1413 | 0.010 |
Why?
|
B-Lymphocytes | 1 | 2016 | 4664 | 0.010 |
Why?
|
Carotenoids | 1 | 2005 | 624 | 0.010 |
Why?
|
Nutrition Assessment | 1 | 2005 | 723 | 0.010 |
Why?
|
Gated Blood-Pool Imaging | 1 | 2002 | 44 | 0.010 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2012 | 6030 | 0.010 |
Why?
|
CD4 Lymphocyte Count | 1 | 2008 | 2557 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 4751 | 0.010 |
Why?
|
Lymphoma, B-Cell | 1 | 2008 | 930 | 0.010 |
Why?
|
Epoetin Alfa | 1 | 2001 | 83 | 0.010 |
Why?
|
Mouth Mucosa | 1 | 2003 | 434 | 0.010 |
Why?
|
Meta-Analysis as Topic | 1 | 2005 | 1342 | 0.010 |
Why?
|
Thyroid Hormones | 1 | 2003 | 390 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2015 | 14554 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2015 | 13029 | 0.010 |
Why?
|
Southeastern United States | 1 | 2000 | 95 | 0.010 |
Why?
|
Endometrium | 1 | 2003 | 424 | 0.010 |
Why?
|
Neuropsychological Tests | 1 | 2013 | 6974 | 0.010 |
Why?
|
Genetic Variation | 1 | 2015 | 6540 | 0.010 |
Why?
|
Aging | 1 | 1999 | 8626 | 0.010 |
Why?
|
Trimetrexate | 1 | 1999 | 15 | 0.010 |
Why?
|
Injections, Subcutaneous | 1 | 2001 | 664 | 0.010 |
Why?
|
Health Services | 1 | 2005 | 758 | 0.010 |
Why?
|
Infection Control | 1 | 2007 | 962 | 0.010 |
Why?
|
Imides | 1 | 1999 | 15 | 0.010 |
Why?
|
Naphthalimides | 1 | 1999 | 21 | 0.010 |
Why?
|
Costs and Cost Analysis | 1 | 2005 | 1679 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2005 | 2885 | 0.010 |
Why?
|
Cardiology | 1 | 2010 | 1658 | 0.010 |
Why?
|
Diet | 1 | 1997 | 7923 | 0.010 |
Why?
|
Needs Assessment | 1 | 2005 | 1146 | 0.010 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 2000 | 772 | 0.010 |
Why?
|
Cost Savings | 1 | 2004 | 925 | 0.010 |
Why?
|
Promoter Regions, Genetic | 1 | 2010 | 5867 | 0.010 |
Why?
|
Decision Trees | 1 | 2000 | 506 | 0.010 |
Why?
|
Drug Prescriptions | 1 | 2008 | 1636 | 0.010 |
Why?
|
Child, Preschool | 1 | 2021 | 40955 | 0.010 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2000 | 599 | 0.010 |
Why?
|
Growth Substances | 1 | 2000 | 783 | 0.010 |
Why?
|
Matrix Metalloproteinases | 1 | 2000 | 391 | 0.010 |
Why?
|
Empirical Research | 1 | 1998 | 120 | 0.010 |
Why?
|
Endothelial Growth Factors | 1 | 2000 | 694 | 0.010 |
Why?
|
Leadership | 1 | 2007 | 1357 | 0.010 |
Why?
|
Fatty Acids | 1 | 2005 | 1806 | 0.010 |
Why?
|
Isoquinolines | 1 | 1999 | 368 | 0.010 |
Why?
|
Health Services Needs and Demand | 1 | 2005 | 1411 | 0.010 |
Why?
|
Genetic Research | 1 | 1998 | 174 | 0.010 |
Why?
|
Health Policy | 1 | 2009 | 2657 | 0.010 |
Why?
|
Lymphokines | 1 | 2000 | 949 | 0.010 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2008 | 1596 | 0.010 |
Why?
|
Immunosuppressive Agents | 1 | 2010 | 4147 | 0.010 |
Why?
|
Risk Management | 1 | 2000 | 571 | 0.010 |
Why?
|
Catheter Ablation | 1 | 2010 | 2746 | 0.010 |
Why?
|
Drug Resistance | 2 | 1992 | 1608 | 0.010 |
Why?
|
Women | 1 | 1998 | 230 | 0.010 |
Why?
|
Rats, Inbred WKY | 1 | 1995 | 158 | 0.010 |
Why?
|
Rats, Inbred SHR | 1 | 1995 | 195 | 0.010 |
Why?
|
Bone Marrow | 1 | 2006 | 2941 | 0.010 |
Why?
|
DNA Methylation | 1 | 2010 | 4282 | 0.010 |
Why?
|
Genomic Library | 1 | 1995 | 193 | 0.010 |
Why?
|
Quality Assurance, Health Care | 1 | 2006 | 2211 | 0.010 |
Why?
|
Hybrid Cells | 1 | 1995 | 441 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2006 | 5975 | 0.010 |
Why?
|
Hemoglobins | 1 | 2001 | 1532 | 0.010 |
Why?
|
Absorption | 1 | 1994 | 248 | 0.010 |
Why?
|
Blood Transfusion | 1 | 2001 | 1296 | 0.010 |
Why?
|
Ultrasonography | 1 | 2007 | 5978 | 0.010 |
Why?
|
Base Sequence | 2 | 1995 | 12797 | 0.010 |
Why?
|
Biological Availability | 1 | 1994 | 396 | 0.010 |
Why?
|
Adenine | 1 | 1999 | 936 | 0.010 |
Why?
|
Head and Neck Neoplasms | 1 | 2007 | 2712 | 0.010 |
Why?
|
Half-Life | 1 | 1994 | 658 | 0.010 |
Why?
|
Injections, Intravenous | 1 | 1995 | 1420 | 0.010 |
Why?
|
Microsatellite Repeats | 1 | 1995 | 800 | 0.010 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2006 | 3328 | 0.010 |
Why?
|
Contrast Media | 1 | 2006 | 5295 | 0.010 |
Why?
|
Molecular Sequence Data | 2 | 1995 | 18112 | 0.010 |
Why?
|
Software | 1 | 2006 | 4434 | 0.010 |
Why?
|
O(6)-Methylguanine-DNA Methyltransferase | 1 | 1992 | 85 | 0.010 |
Why?
|
X Chromosome | 1 | 1995 | 815 | 0.010 |
Why?
|
Counseling | 1 | 2000 | 1521 | 0.010 |
Why?
|
Genes | 1 | 1995 | 1892 | 0.010 |
Why?
|
Species Specificity | 1 | 1995 | 2479 | 0.010 |
Why?
|
DNA Primers | 1 | 1995 | 2892 | 0.010 |
Why?
|
Genome | 1 | 1998 | 1803 | 0.010 |
Why?
|
Alkaline Phosphatase | 1 | 1992 | 865 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2000 | 4414 | 0.010 |
Why?
|
Caregivers | 1 | 2000 | 2074 | 0.000 |
Why?
|
Electrocardiography | 1 | 2002 | 6440 | 0.000 |
Why?
|
Random Allocation | 1 | 1990 | 2425 | 0.000 |
Why?
|
Dietary Fats | 1 | 1993 | 2017 | 0.000 |
Why?
|
Rats, Sprague-Dawley | 1 | 1995 | 8300 | 0.000 |
Why?
|
Private Practice | 1 | 1985 | 154 | 0.000 |
Why?
|
Lymphocytes | 1 | 1992 | 2614 | 0.000 |
Why?
|
Membrane Glycoproteins | 1 | 1992 | 3769 | 0.000 |
Why?
|
Anti-Bacterial Agents | 1 | 1999 | 7153 | 0.000 |
Why?
|